ALX ONCOLOGY HOLDINGS INC
No SEC Form 4 filings for $ALXO in the last 30 days.
See all $ALXO insider activity →ALX Oncology (ALXO) exchanged 13.35M shares for pre-funded warrants with key shareholders, including Blackstone affiliates, RA Capital, and venBio. The warrants, exercisable at $0.001 per share, have no expiration and include ownership blockers. The deals aim to optimize capital structure and manage ownership thresholds, with settlement expected on Oct 15, 2026.
ALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 14, 2026, ALX Oncology Holdings Inc. (the “Company”) entered into separate privately-negotiated exchange agreements (each, an “Exchange Agreement”), with certain stockholders of the Company (collectively, the “Stock
ALX Oncology (Nasdaq: ALXO) reported Q2 2026 results and a corporate update. Cash, cash equivalents and investments were $153.4 million as of June 30, 2026. R&D fell to $13.1 million from $18.0 million year over year, and GAAP net loss was $18.0 million ($0.13/share). The company said ASPEN-09-Breast topline data from 80 patients is expected mid-2027, and ALX2004 safety data is expected in 2H 2026.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ALXO (ALX ONCOLOGY HOLDINGS INC). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent ALXO coverage spans corporate actions, earnings and financial news.
The warrant exchanges could dilute existing shareholders but improve ownership structure, potentially supporting the stock price.
The exchange of shares for pre‑funded warrants may dilute existing shareholders but provides cash or cashless exercise flexibility.
Clinical-program timelines and balance-sheet refinancing are the key near-term drivers for ALXO risk and valuation expectations.
Near-term trading focus is on cash runway, cost trajectory, and whether clinical enrollment and safety timelines stay on track toward mid-2027 topline.
Board leadership changes can shift governance priorities and investor sentiment, but the filing provides no operational or financial guidance changes.
AlphAI scores every news story that mentions ALXO with an AI model for sentiment and relevance, and aggregates insider trades from ALX ONCOLOGY HOLDINGS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
ALX Oncology (ALXO) exchanged 13.35M shares for pre-funded warrants with key shareholders, including Blackstone affiliates, RA Capital, and venBio. The warrants, exercisable at $0.001 per share, have no expiration and include ownership blockers. The deals aim to optimize capital structure and manage ownership thresholds, with settlement expected on Oct 15, 2026.
1 min readALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 14, 2026, ALX Oncology Holdings Inc. (the “Company”) entered into separate privately-negotiated exchange agreements (each, an “Exchange Agreement”), with certain stockholders of the Company (collectively, the “Stock
1 min readALX Oncology (Nasdaq: ALXO) reported Q2 2026 results and a corporate update. Cash, cash equivalents and investments were $153.4 million as of June 30, 2026. R&D fell to $13.1 million from $18.0 million year over year, and GAAP net loss was $18.0 million ($0.13/share). The company said ASPEN-09-Breast topline data from 80 patients is expected mid-2027, and ALX2004 safety data is expected in 2H 2026.
7 min readALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update – On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy
7 min readALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001810182 false 0001810182 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,
2 min readALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001810182 0001810182 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25,
4 min readALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001810182 false 0001810182 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
2 min readMarketBeat compares ALX Oncology (ALXO) and Medicus Pharma (MDCX) on earnings, risk, valuation, profitability, ownership and analyst ratings. ALXO has a consensus target of $4.60 (134.7% upside) versus MDCX’s $9.00 (2,817.3%). ALXO is described as more affordable by P/E; ALXO beta is 0.41 and institutional ownership 98%.
4 min readALX Oncology Holdings Inc. (ALXO) has filed its definitive proxy statement (DEF 14A) for its 2026 annual stockholders' meeting, to be held virtually on June 10, 2026. Stockholders will vote on the election of three Class III directors, an advisory "say-on-pay" resolution for named executive officer compensation, and the ratification of KPMG LLP as the independent registered public accounting firm. The filing also details executive compensation, including base salaries, cash incentives, and equity awards, along with information on director independence, board structure, and related-party transactions.
2 min readALX Oncology Holdings Inc is
3 min read
